Deadline Approaching: Mereo BioPharma Class Action for Investors by April 6, 2026

Class Action Alert: Mereo BioPharma Investors

As of April 2, 2026, the prominent plaintiffs' law firm, Berger Montague PC, has informed investors of a crucial class action lawsuit concerning Mereo BioPharma Group plc (NASDAQ: MREO). This case is directed at those who purchased American Depositary Shares (ADS) between June 5, 2023, and December 26, 2025. If you are among these investors, it is imperative that you understand the situation and your rights under this lawsuit.

Background of the Case

Mereo BioPharma is a biopharmaceutical company headquartered in London, UK, that specializes in developing therapies for rare conditions. Throughout the relevant period of the class action, the company made several optimistic announcements regarding its Phase 3 programs known as ORBIT and COSMIC, which aimed to evaluate the efficacy of setrusumab in treating Osteogenesis Imperfecta. These assertions painted a picture of positive outcomes that elicited hopes of successful results from investors.

However, in a stark turn of events on December 29, 2025, Mereo reported disappointing results; neither of its clinical trials reached the primary endpoint of reducing the annualized clinical fracture rate. This revelation resulted in a staggering loss for investors, with the price of its ADS plummeting more than 87%, dropping from $2.31 per share on December 26, 2025, to just $0.29 by the end of December 29, 2025.

Claiming Your Rights

Investors affected by this situation have until April 6, 2026, to file their motion to serve as lead plaintiff in the class action. This is a critical deadline, and those interested in asserting their rights should not delay in seeking guidance from legal counsel experienced in securities fraud cases. Being appointed as a lead plaintiff can provide not only a voice for your investment concerns but also may lead to potential recoveries if the lawsuit is successful.

Berger Montague encourages investors to reach out to their legal team for more information. Interested parties can contact Andrew Abramowitz at [email protected] or (215) 875-3015, or Caitlin Adorni at [email protected] or (267) 764-4865.

About Berger Montague

Berger Montague stands out as one of America's leading law firms, with a strong focus on complex civil litigation, class actions, and mass torts across various courts in the United States. The firm boasts an impressive record, having secured over $2.4 billion in post-trial judgments in 2025 alone. This wealth of experience, accumulated over more than 55 years of operation, has established Berger Montague as a powerhouse in many fields including securities litigation, antitrust, consumer protection, and environmental law.

If you believe you have been impacted by Mereo BioPharma's disclosures, it's crucial to act now to ensure your rights are recognized and potentially compensated. Time is of the essence, particularly with the fast-approaching deadlines. Understanding your rights can make a significant difference in the outcome of this case.